Comparative effectiveness and cost evaluation of Risankizumab and Adalimumab in the management of psoriasis: a real-world study in Saudi Arabia.

Cost Eff Resour Alloc · 2023 · PMC10709881 · PMID 38071302

Europe PMC DOI

hedged sentence

0.1628

closest p · 3.3× alpha

0.1628

boldest claim

The sentences

did not reach statistical significancep -value = 0.1628not close (p > 0.1)

However, after adjusting for variables such as age, gender, illness and treatment durations, and the number of comorbidities, this observation did not reach statistical significance (OR = 2.75, 95% CI = [0.667–11.14], p -value = 0.1628).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.